Regeneron Files 8-K on Financial Results & Operations
Ticker: REGN · Form: 8-K · Filed: Feb 2, 2024 · CIK: 872589
| Field | Detail |
|---|---|
| Company | Regeneron Pharmaceuticals, Inc. (REGN) |
| Form Type | 8-K |
| Filed Date | Feb 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-results, operations, 8-K
TL;DR
**Regeneron just dropped an 8-K on financial results, get ready for potential stock movement.**
AI Summary
Regeneron Pharmaceuticals, Inc. filed an 8-K on February 2, 2024, to report on its results of operations and financial condition. This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. For shareholders, this matters because it offers transparency into how the company is performing, potentially influencing stock price based on whether the results meet or exceed expectations.
Why It Matters
This filing provides investors with the latest financial performance data for Regeneron, directly impacting their assessment of the company's value and future growth potential.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial results and operations, not indicating any immediate new risks.
Analyst Insight
Investors should await the full financial statements and exhibits referenced in this 8-K to make informed decisions, as this filing only signals the release of such information.
Key Numbers
- February 2, 2024 — Date of Report (Indicates the effective date of the reported events and filing.)
- 000-19034 — Commission File Number (Unique identifier for Regeneron's filings with the SEC.)
- $.001 — Par Value per Share (The nominal value assigned to each share of common stock.)
Key Players & Entities
- REGENERON PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
- February 2, 2024 (date) — date of earliest event reported and filing date
- 000-19034 (other) — Commission File Number for Regeneron
- NASDAQ Global Select Market (other) — exchange where Regeneron's Common Stock is registered
- $.001 per share (dollar_amount) — par value of Regeneron's Common Stock
Forward-Looking Statements
- Regeneron's stock price will react to the detailed financial results once they are fully disclosed. (REGENERON PHARMACEUTICALS, INC.) — high confidence, target: Q1 2024
FAQ
What is the primary purpose of this 8-K filing by Regeneron Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing, dated February 2, 2024, is to report on the 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' of Regeneron Pharmaceuticals, Inc., as indicated by the 'ITEM INFORMATION' sections.
On what date was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is February 2, 2024, as stated under 'Date of Report (Date of earliest event reported): February 2, 2024'.
What is the trading symbol and the exchange where Regeneron Pharmaceuticals, Inc.'s Common Stock is registered?
Regeneron Pharmaceuticals, Inc.'s Common Stock has the trading symbol REGN and is registered on the NASDAQ Global Select Market, as detailed under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the address and telephone number of Regeneron Pharmaceuticals, Inc.'s principal executive offices?
The address of Regeneron Pharmaceuticals, Inc.'s principal executive offices is 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707, and their telephone number is (914) 847-7000, according to the filing.
Is Regeneron Pharmaceuticals, Inc. classified as an emerging growth company?
No, Regeneron Pharmaceuticals, Inc. is not classified as an emerging growth company, as indicated by the unchecked box next to 'Emerging growth company' in the filing.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-02-02 07:16:11
Filing Documents
- regn-20240202.htm (8-K) — 23KB
- exhibit991q42023.htm (EX-99.1) — 547KB
- image0a12.jpg (GRAPHIC) — 8KB
- 0001804220-24-000006.txt ( ) — 748KB
- regn-20240202.xsd (EX-101.SCH) — 2KB
- regn-20240202_lab.xml (EX-101.LAB) — 23KB
- regn-20240202_pre.xml (EX-101.PRE) — 13KB
- regn-20240202_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 2, 2024, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2023. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02. The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release, dated February 2, 2024, Reporting Fourth Quarter and Full Year 2023 Financial and Operating Results. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 2, 2024 REGENERON PHARMACEUTICALS, INC. By: /s/ Joseph J. LaRosa Name: Joseph J. LaRosa Title: Executive Vice President, General Counsel and Secretary